LDN and treatment of cancer

As many of you know, I have been using LDN for the last few years in treating all forms of Autoimmune diseases. Some of the results have been amazing, as some of you have witnessed. This paper is of great interest as I have 5 patients at present on LDN for treatment of their cancers, at their request. I do not expect it to cure their cancers but to assist the other cancer treatments they are on and to generally make them feel better. The point to remember is that LDN is very safe in these low doses and is not expensive, compared to the cost of most anti-cancer treatments. My major problem is with specialists, who take their patients off the LDN, as they obviously know nothing about LDN. This is frustrating to say the least.

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

  • Authors:
    • Wai M. Liu
    • Katherine A. Scott
    • Jayne L. Dennis
    • Elwira Kaminska
    • Alan J. Levett
    • Angus G. Dalgleish
  • View Affiliations
    Affiliations: Department of Oncology, Institute for Infection and Immunity, St. George’s University of London, London SW17 0RE, UK

<!–

  • Corresponding author: Author name

–>

  • Published online on:Tuesday, June 7, 2016

This article is mentioned in:

Abstract

It has been reported that lower doses of the opioid antagonist naltrexone are able to reduce tumour growth by interfering with cell signalling as well as by modifying the immune system. We have evaluated the gene expression profile of a cancer cell line after treatment with low-dose naltrexone (LDN), and assessed the effect that adapting treatment schedules with LDN may have on enhancing efficacy. LDN had a selective impact on genes involved with cell cycle regulation and immune modulation. Similarly, the pro-apoptotic genes BAD and BIK1 were increased only after LDN. Continuous treatment with LDN had little effect on growth in different cell lines; however, altering the treatment schedule to include a phase of culture in the absence of drug following an initial round of LDN treatment, resulted in enhanced cell killing. Furthermore, cells pre-treated with LDN were more sensitive to the cytotoxic effects of a number of common chemotherapy agents. For example, priming HCT116 with LDN before treatment with oxaliplatin significantly increased cell killing to 49±7.0 vs. 14±2.4% in cultures where priming was not used. Interestingly, priming with NTX before oxaliplatin resulted in just 32±1.8% cell killing. Our data support further the idea that LDN possesses anticancer activity, which can be improved by modifying the treatment schedule.

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on June 8, 2016, in Uncategorized. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: